AbCellera Biologics Inc. has provided an update on its pipeline and recent developments. The company reported advancement of its internal programs, with two molecules—ABCL635 and ABCL575—now in clinical trials. ABCL635, targeting NK3R, is in a Phase 1/2 trial focused on endocrinology and women's health, while ABCL575, targeting OX40L, is in a Phase 1 trial for immunology and inflammation. Two additional candidates, ABCL688 and ABCL386, are progressing through IND-enabling studies in the areas of autoimmunity and oncology, respectively. The company has also initiated activities at its new clinical manufacturing facility and maintains over $680 million in available liquidity. AbCellera plans to nominate at least one more development candidate for IND-enabling studies in the coming year. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abcellera Biologics Inc. published the original content used to generate this news brief on January 14, 2026, and is solely responsible for the information contained therein.